Previous studies have suggested that sEH inhibition may confer protective effects in Alzheimer’s disease [23], Parkinson’s disease [24], cardiovascular diseases [25,26], preeclampsia [27], and inflammatory bowel disease [26], rendering sEH inhibition a potential treatment target. Here, EPHX2 is linked to Parkinson disease.